| 86.71 1.24 (1.45%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 106.24 |
1-year : | 112.71 |
| Resists | First : | 90.96 |
Second : | 96.5 |
| Pivot price | 88.14  |
|||
| Supports | First : | 82 |
Second : | 68.22 |
| MAs | MA(5) : | 88.42 |
MA(20) : | 89.45 |
| MA(100) : | 64.36 |
MA(250) : | 42.68 |
|
| MACD | MACD : | 1.3 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 42 |
D(3) : | 48.2 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 96.5 | Low : | 16.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNTH ] has closed above bottom band by 35.2%. Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.84 - 89.19 | 89.19 - 89.5 |
| Low: | 84.05 - 84.47 | 84.47 - 84.84 |
| Close: | 85.92 - 86.62 | 86.62 - 87.22 |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Sat, 09 May 2026
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
Fri, 08 May 2026
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: 47.87% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Wed, 06 May 2026
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Tue, 05 May 2026
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Tue, 05 May 2026
DNTH: Advancing two best-in-disease autoimmune therapies with strong clinical data and financial runway - TradingView
Tue, 05 May 2026
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 4.198e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 9,190 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7782e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -24 % |
| Return on Assets (ttm) | 486.2 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 2.04e+006 % |
| Gross Profit (p.s.) | -374.29 |
| Sales Per Share | -182.77 |
| EBITDA (p.s.) | 9.71429e+006 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -129 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.48 |
| Price to Cash Flow | 1.59 |
| Dividend | 0 |
| Forward Dividend | 6.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|